Sodium Gluconate

Summary

Sodium Gluconate (CHEMBL2068884) is an approved small molecule; indicated across 2 conditions including brain neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Chemistry: 216.12 Da · C6H9NaO7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2068884
Name	Sodium Gluconate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	23664049
Molecular formula	C6H9NaO7
Molecular weight	216.12
InChIKey	MSXHSNHNTORCAW-GGLLEASOSA-M

SMILES: [C@@H]1([C@@H]([C@H](O[C@@H]([C@@H]1O)O)C(=O)[O-])O)O.[Na+]

IUPAC name: sodium (2S,3S,4S,5R,6S)-3,4,5,6-tetrahydroxyoxane-2-carboxylate

Also known as: Bvd addicrete, Clewat gl, D-gluconic acid, monosodium salt, E-576, E576, FEMA NO. 4934, Gluconate sodium, Gluconic acid sodium salt, Helshas a, INS NO.576, INS-576

Patent coverage: 13 distinct patent families (22 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
brain neoplasm	2	MONDO:0021211	EFO:0003833

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).